Pulmonary drug delivery systems for tuberculosis treatment

Global tuberculosis report (2014)

Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702 · see citing works

Aerosol Technology Properties, Behavior, and Measurement of Airborne Particles

Laucks, M. L. (2000) · Journal of Aerosol Science · doi:10.1016/s0021-8502(99)00571-6 · Cited by 3,426 · see citing works

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis

Blumberg, H. M., Burman, W. J., Chaisson, R. E., Daley, C. L., Etkind, S. C., Friedman, L. N., Fujiwara, P., Grzemska, M., Hopewell, P. C., Iseman, M. D., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,936 · see citing works

Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This Statement was endorsed by the Council of the Infectious Disease Society of America, September 1999

(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,524 · see citing works

Large Porous Particles for Pulmonary Drug Delivery

Edwards, D. A., Hanes, J. S., Caponetti, G., Hrkach, J. S., Ben-Jebria, A., Eskew, M. L., Mintzes, J. D., Deaver, D. R., Lotan, N., & Langer, R. (1997) · Science · doi:10.1126/science.276.5320.1868 · Cited by 1,176 · see citing works

Deposition of particles in the human respiratory tract in the size range 0.005–15 μm

Heyder, J., Gebhart, J., Rudolf, G., Schiller-Scotland, C. F., & STAHLHOFEN, W. (1986) · Journal of Aerosol Science · doi:10.1016/0021-8502(86)90035-2 · Cited by 1,030 · see citing works

Global Tuberculosis Control 2011, WHO Report 2011

Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022 · see citing works

Administration of substances to laboratory animals: routes of administration and factors to consider.

Turner, P. V., Brabb, T., Pekow, C. A., & Vasbinder, M. A. (2011) · PubMed Central · Cited by 982 · see citing works

Tuberculosis: Pathogenesis, Protection and Control

(1996) · Nature Medicine · doi:10.1038/nm0296-244b · Cited by 977 · see citing works

Development of Nanoparticles for Antimicrobial Drug Delivery

Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 890 · see citing works

Lung biology in health and disease

Horsmanheimo, M., & Fudenberg, H. H. (1977) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(77)90040-x · Cited by 798 · see citing works

Treatment of Multidrug-Resistant Tuberculosis

Wood, A. J. J., & Iseman, M. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291108 · Cited by 712 · see citing works

Nanoparticles for drug delivery to the lungs

Sung, J. C., Pulliam, B., & Edwards, D. A. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.09.005 · Cited by 644 · see citing works

Trojan particles: Large porous carriers of nanoparticles for drug delivery

Tsapis, N., Bennett, D., Jackson, B., Weitz, D. A., & Edwards, D. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182233999 · Cited by 546 · see citing works

Tuberculosis in Patients with the Acquired Immunodeficiency Syndrome: Clinical Features, Response to Therapy, and Survival

Chaisson, R. E., Schecter, G. F., Theuer, C. P., Rutherford, G. W., Echenberg, D. F., & Hopewell, P. C. (1987) · American Review of Respiratory Disease · doi:10.1164/ajrccm/136.3.570 · Cited by 453 · see citing works

New insights into the function of granulomas in human tuberculosis

Ulrichs, T., & Kaufmann, S. H. E. (2006) · Journal of Pathology · doi:10.1002/path.1906 · Cited by 421 · see citing works

Lippincott's Illustrated Reviews: Pharmacology

Whalen, K., Finkel, R. S., & Panavelil, T. A. (1991) · Cited by 415 · see citing works

Delivery strategies for sustained drug release in the lungs

Loira-Pastoriza, C., Todoroff, J., & Rita Vanbever, A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 395 · see citing works

Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis

Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 389 · see citing works

Liposomes: A Review of Manufacturing Techniques and Targeting Strategies

Maherani, B., Arab‐Tehrany, E., Mozafari, M. R., Gaïani, C., & Linder, M. (2011) · Current Nanoscience · doi:10.2174/157341311795542453 · Cited by 369 · see citing works

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol

Condos, R., Rom, W. N., & Schluger, N. W. (1997) · The Lancet · doi:10.1016/s0140-6736(96)12273-x · Cited by 318 · see citing works

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318 · see citing works

Formulation and Physical Characterization of Large Porous Particles for Inhalation

Rita Vanbever, A., Mintzes, J. D., Wang, J., Nice, J., Chen, D., Batycky, R., Langer, R., & Edwards, D. A. (1999) · Pharmaceutical Research · doi:10.1023/a:1018910200420 · Cited by 315 · see citing works

Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis

Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314 · see citing works

Manual of clinical microbiology

Lennette, E. H. (1982) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(82)90036-2 · Cited by 302 · see citing works

Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance

Bosquillon, C., Lombry, C., Véronique Préat, A., & Rita Vanbever, A. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00362-x · Cited by 296 · see citing works

Tuberculosis in patients with the acquired immunodeficiency syndrome

Richard, R. (1987) · Medical Entomology and Zoology · Cited by 294 · see citing works

Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response

Kanchan, V., & Panda, A. K. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.015 · Cited by 283 · see citing works

Global Tuberculosis Control: WHO Report 2011

Williams, C. (2012) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2012.00928.x · Cited by 268 · see citing works

Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages

Vyas, S. P., Kannan, M., Jain, S., Mishra, V. K., & Singh, P. (2003) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.08.017 · Cited by 262 · see citing works

Dry powder inhalers for pulmonary drug delivery

Frijlink, H. W., & de Boer, A. H. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.67 · Cited by 259 · see citing works

Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis

Sharma, A., Sharma, S., & Khuller, G. K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh411 · Cited by 251 · see citing works

Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery

Sung, J. C., Padilla, D. J., Garcia‐Contreras, L., VerBerkmoes, J. L., Durbin, D., Peloquin, C. A., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9894-2 · Cited by 245 · see citing works

Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases

Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.020 · Cited by 245 · see citing works

Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Manufacture and Characterization

O’Hara, P. J., & Hickey, A. J. (2000) · Pharmaceutical Research · doi:10.1023/a:1007527204887 · Cited by 242 · see citing works

Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis

Pandey, R., Zahoor, A., Sharma, S., & Khuller, G. K. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.07.001 · Cited by 220 · see citing works

Tuberculosis chemotherapy: current drug delivery approaches

du Toit, L. C., Pillay, V., & Danckwerts, M. P. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-118 · Cited by 213 · see citing works

Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis

Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201 · see citing works

Epidemiology of selected mycobacteria that infect humans and other animals

Ashford, D. A., Whitney, E. A. S., Raghunathan, P. L., & Cosivi, O. (2001) · Scientific and Technical Review (World Organisation for Animal Health) · doi:10.20506/rst.20.1.1266 · Cited by 191 · see citing works

Antitubercular inhaled therapy: opportunities, progress and challenges

Pandey, R., & Khuller, G. K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki027 · Cited by 188 · see citing works

Golden Holocaust: Origins of the Cigarette Catastrophe and the Case for Abolition

Daube, M. (2012) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2012.00927.x · Cited by 187 · see citing works

One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis

Ohashi, K., Kabasawa, T., Ozeki, T., & Okada, H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.027 · Cited by 178 · see citing works

The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.

Blomberg, B., Spinaci, S., Fourie, B. P., & Laing, R. O. (2001) · Europe PMC (PubMed Central) · Cited by 176 · see citing works

Inhalable microparticles containing large payload of anti-tuberculosis drugs

Muttil, P., Kaur, J. P., Kumar, K., Yadav, A. B., Sharma, R., & Misra, A. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.06.006 · Cited by 173 · see citing works

Delivery of Biotherapeutics by Inhalation Aerosol

Niven, R. W. (1995) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v12.i2-3.20 · Cited by 164 · see citing works

Immunopathogenesis of Pulmonary Tuberculosis

Dannenberg, A. M. (1993) · Hospital Practice · doi:10.1080/21548331.1993.11442738 · Cited by 164 · see citing works

Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in An Infectious Disease Model

Suarez, S., O’Hara, P. J., Kazantseva, M., Newcomer, C. E., Hopfer, R. L., McMurray, D. N., & Hickey, A. J. (2001) · Pharmaceutical Research · doi:10.1023/a:1013094112861 · Cited by 159 · see citing works

Airways delivery of rifampicin microparticles for the treatment of tuberculosis

Suarez, S. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.431 · Cited by 156 · see citing works

Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery

Willis, L., Hayes, D., & Mansour, H. M. (2012) · Lung · doi:10.1007/s00408-011-9360-x · Cited by 148 · see citing works

Inhaled Drug Delivery for Tuberculosis Therapy

Muttil, P., Wang, C., & Hickey, A. J. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9957-4 · Cited by 145 · see citing works

Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin

Makino, K., Nakajima, T., Shikamura, M., Ito, F., Ando, S., Kochi, C., Inagawa, H., Soma, G., & Terada, H. (2004) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2004.03.018 · Cited by 145 · see citing works

Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig Model

Garcia‐Contreras, L., Fiegel, J., Telko, M. J., Elbert, K. J., Hawi, A. A., Thomas, M., VerBerkmoes, J. L., Germishuizen, W. A., Fourie, P. B., Hickey, A. J., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01164-06 · Cited by 139 · see citing works

New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes

Lienhardt, C., Vernon, A., & Raviglione, M. C. (2010) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328337580c · Cited by 137 · see citing works

Dry powder platform for pulmonary drug delivery

Daniher, D., & Zhu, J. (2008) · Particuology · doi:10.1016/j.partic.2008.04.004 · Cited by 133 · see citing works

Delivery of rifampicin–PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis

Hirota, K., Hasegawa, T., Nakajima, T., Inagawa, H., Kohchi, C., Soma, G., Makino, K., & Terada, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.020 · Cited by 129 · see citing works

Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice

Deol, P., Khuller, G. K., & Joshi, K. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1211 · Cited by 128 · see citing works

Isoniazid Proliposome Powders for Inhalation—Preparation, Characterization and Cell Culture Studies

Rojanarat, W., Changsan, N., Tawithong, E., Pinsuwan, S., Chan, H., & Srichana, T. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12074414 · Cited by 120 · see citing works

Respirable nanocarriers as a promising strategy for antitubercular drug delivery

Mehanna, M. M., Mohyeldin, S. M., & Elgindy, N. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.038 · Cited by 119 · see citing works

New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series]

Grosset, J. H. E., Singer, T. G., & Bishai, W. R. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0277 · Cited by 118 · see citing works

Polymer Based Drug Delivery Systems for Mycobacterial Infections

Pandey, R., & Khuller, G. K. (2004) · Current Drug Delivery · doi:10.2174/1567201043334669 · Cited by 116 · see citing works

Use of Microsphere Technology for Targeted Delivery of Rifampin to Mycobacterium tuberculosis -Infected Macrophages

Barrow, E. L. W., Winchester, G. A., Staas, J. K., Quenelle, D. C., & Barrow, W. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2682 · Cited by 113 · see citing works

Physicochemical Characterization and Stability of Rifampicin Liposome Dry Powder Formulations for Inhalation

Changsan, N., Chan, H., Separovic, F., & Srichana, T. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21441 · Cited by 108 · see citing works

Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers

Saari, M., Vidgren, M. T., Koskinen, M. O., Turjanmaa, V., & Nieminen, M. M. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00398-6 · Cited by 105 · see citing works

No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes

Canonico, A. E., Plitman, J. D., Conary, J. T., Meyrick, B. O., & Brigham, K. L. (1994) · Journal of Applied Physiology · doi:10.1152/jappl.1994.77.1.415 · Cited by 103 · see citing works

A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics

Chan, J. G. Y., Chan, H., Prestidge, C. A., Denman, J. A., Young, P. M., & Traini, D. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.08.007 · Cited by 100 · see citing works

Recent advances in liposomal dry powder formulations: preparation and evaluation

Misra, A. R., Jinturkar, K., Patel, D. H., Lalani, J., & Chougule, M. B. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802652309 · Cited by 99 · see citing works

Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice

Verma, R. K., Kaur, J. P., Kumar, K., Yadav, A. B., & Misra, A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00153-08 · Cited by 96 · see citing works

Preparation and in Vivo Evaluation of a Dry Powder for Inhalation of Capreomycin

Fiegel, J., Garcia‐Contreras, L., Thomas, M., VerBerkmoes, J. L., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9381-6 · Cited by 95 · see citing works

Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion

Abu‐Dahab, R., Schäfer, U. F., & Lehr, C. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00147-6 · Cited by 95 · see citing works

Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra

Sharma, R., Muttil, P., Yadav, A. B., Rath, S. K., Bajpai, V. K., Mani, U., & Misra, A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl533 · Cited by 94 · see citing works

Acute Effects of Liposome Aerosol Inhalation on Pulmonary Function in Healthy Human Volunteers

Thomas, D. A., Myers, M. A., Wichert, B. M., Schreier, H., & Gonzalez‐Rothi, R. J. (1991) · CHEST Journal · doi:10.1378/chest.99.5.1268 · Cited by 83 · see citing works

Slow Release Formulations of Inhaled Rifampin

Coowanitwong, I., Arya, V., Kulvanich, P., & Hochhaus, G. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9044-5 · Cited by 79 · see citing works

Inhaled pyrazinamide proliposome for targeting alveolar macrophages

Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., & Srichana, T. (2012) · Drug Delivery · doi:10.3109/10717544.2012.721144 · Cited by 79 · see citing works

Six-month Therapy with Aerosolized Interferon-γ for Refractory Multidrug-Resistant Pulmonary Tuberculosis

Koh, W., Kwon, O. J., Suh, G. Y., Chung, M. P., Kim, H., Lee, N. Y., Kim, T., & Lee, K. S. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.2.167 · Cited by 79 · see citing works

Incorporation of Antibiotics in Liposomes Designed for Tuberculosis Therapy by Inhalation

Justo, O. R., & Moraes, Â. M. (2003) · Drug Delivery · doi:10.1080/713840401 · Cited by 77 · see citing works

Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs

Garcia‐Contreras, L., Sung, J. C., Muttil, P., Padilla, D., Telko, M., VerBerkmoes, J. L., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01471-09 · Cited by 76 · see citing works

In vitro evaluation of inhalable isoniazid‐loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis

Chimote, G., & Banerjee, R. (2010) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.31608 · Cited by 75 · see citing works

An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor‐ᆇ

Cosgrove, B. D., Cheng, C., Pritchard, J. R., Stolz, D. B., Lauffenburger, D. A., & Griffith, L. G. (2008) · Hepatology · doi:10.1002/hep.22335 · Cited by 75 · see citing works

Enhanced Anti-Inflammation of Inhaled Dexamethasone Palmitate Using Mannosylated Liposomes in an Endotoxin-Induced Lung Inflammation Model

Wijagkanalan, W., Higuchi, Y., Kawakami, S., Teshima, M., Sasaki, H., & Hashida, M. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050153 · Cited by 74 · see citing works

Direct lung delivery of para-aminosalicylic acid by aerosol particles

Tsapis, N., Bennett, D., O'Driscoll, K. M., Shea, K., Lipp, M., Fu, K., Clarke, R. W., Deaver, D. R., Yamins, D. L. K., Wright, J. E., et al. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.08.016 · Cited by 72 · see citing works

Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation

Sung, J. C., Garcia‐Contreras, L., VerBerkmoes, J. L., Peloquin, C. A., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01389-08 · Cited by 72 · see citing works

Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance

Cardona, P.-J. (2012) · InTech eBooks · doi:10.5772/2477 · Cited by 71 · see citing works

Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug

Sethuraman, V. V., & Hickey, A. J. (2002) · AAPS PharmSciTech · doi:10.1208/pt030428 · Cited by 68 · see citing works

Levofloxacin-Proliposomes: Opportunities for Use in Lung Tuberculosis

Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., & Srichana, T. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4030385 · Cited by 67 · see citing works

Did we reach the 2005 targets for tuberculosis control?

Dye, C. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.06.037580 · Cited by 66 · see citing works

Effects of Gender, AIDS, and Acetylator Status on Intrapulmonary Concentrations of Isoniazid

Conte, J. E., Golden, J. A., McQuitty, M., Kipps, J., Duncan, S., McKenna, E., & Zurlinden, E. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2358-2364.2002 · Cited by 65 · see citing works

Adjunctive Salvage Therapy with Inhaled Aminoglycosides for Patients with Persistent Smear-Positive Pulmonary Tuberculosis

Sacks, L. V., Pendle, S., Orlovic, D., Andre, M., Popara, M., Moore, G. A., Thonell, L., & Hurwitz, S. (2001) · Clinical Infectious Diseases · doi:10.1086/317524 · Cited by 64 · see citing works

Selective delivery of rifampicin incorporated into poly(dl-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette–Guérin

Yoshida, A., Matumoto, M., Hshizume, H., Oba, Y., Tomishige, T., Inagawa, H., Kohchi, C., Hino, M., Ito, F., Tomoda, K., et al. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.06.004 · Cited by 63 · see citing works

Nebulization of liposome encapsulated antitubercular drugs in guinea pigs

Pandey, R., Sharma, S., & Khuller, G. K. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.04.004 · Cited by 63 · see citing works

Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs

Prabakaran, D. S., Singh, P., Jaganathan, K. S., & Vyas, S. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.11.013 · Cited by 62 · see citing works

Formation of Inhalable Rifampicin–Poly(l-lactide) Microparticles by Supercritical Anti-solvent Process

Patomchaiviwat, V., Paeratakul, O., & Kulvanich, P. (2008) · AAPS PharmSciTech · doi:10.1208/s12249-008-9152-7 · Cited by 62 · see citing works

Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages

Zhou, H., Zhang, Y., Biggs, D. L., Manning, M. C., Randolph, T. W., Christians, U., Hybertson, B. M., & Ng, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.009 · Cited by 61 · see citing works

Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels

Agrawal, S., Singh, I., Kaur, K. J., Bhade, S. R., Kaul, C. L., & Panchagnula, R. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.02.019 · Cited by 61 · see citing works

Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance

Shah, S. P., & Misra, A. R. (2004) · AAPS PharmSciTech · doi:10.1208/pt050465 · Cited by 58 · see citing works

Iron enhances the antituberculous activity of pyrazinamide

Somoskövi, Á. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh042 · Cited by 58 · see citing works

Sustained release of insulin from insoluble inhaled particles

Rita Vanbever, A., Jebria, A. B., Mintzes, J. D., Langer, R., & Edwards, D. A. (1999) · Drug Development Research · doi:10.1002/(sici)1098-2299(199912)48:4 · Cited by 56 · see citing works

Pulmonary Delivery of Inhalable Nanoparticles: Dry Powder Inhalers

Alhallak, K., Sarfraz, M., Azarmi, S., Roa, W., Finlay, W. H., & Löbenberg, R. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.100 · Cited by 55 · see citing works

Liposomes for Drug Delivery to the Respiratory Tract

Taylor, K. M. G., & Fan, S. J. (1993) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049309038764 · Cited by 52 · see citing works

Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: Avoiding crystal growth using excipients

Pham, D.-D., Fattal, E., Ghermani, N., Guiblin, N., & Tsapis, N. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.016 · Cited by 51 · see citing works

Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization

Schoubben, A., Blasi, P., Marenzoni, M. L., Barberini, L., Giovagnoli, S., Cirotto, C., & Ricci, M. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.11.005 · Cited by 48 · see citing works

Monocyte Recruitment in Tuberculosis and Sarcoidosis

Schmitt, E., Meuret, G. H., & Stix, L. (1977) · British Journal of Haematology · doi:10.1111/j.1365-2141.1977.tb00557.x · Cited by 47 · see citing works

Pharmaceutical aerosols for the treatment and prevention of Tuberculosis

Hanif, S. N. M., & Garcia‐Contreras, L. (2012) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2012.00118 · Cited by 45 · see citing works

Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres

Tomoda, K., & Makino, K. (2006) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2006.11.030 · Cited by 44 · see citing works

Monitoring safety of liposomes containing rifampicin on respiratory cell lines andin vitroefficacy againstMycobacterium bovisin alveolar macrophages

Changsan, N., Nilkaeo, A., Pungrassami, P., & Srichana, T. (2009) · Journal of drug targeting · doi:10.3109/10611860903079462 · Cited by 42 · see citing works

Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage

Kumar, G. S. V., Vadakkan, M. V., Annapoorna, Sivakumar, M., & Mundayoor, S. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47456 · Cited by 41 · see citing works

Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy.

Yadav, A. B., Sharma, R., Muttil, P., Singh, A. K., Verma, R. K., Mohan, M., Patel, S. K. S., & Misra, A. (2009) · PubMed · Cited by 36 · see citing works

In vitro and in vivo evaluation of the effects of PLA microparticle crystallinity on cellular response

Biggs, D. L., Lengsfeld, C., Hybertson, B. M., Ng, K., Manning, M. C., & Randolph, T. W. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00325-0 · Cited by 34 · see citing works

Overview of Clinical Tuberculosis

Hopewell, P. C., & Jasmer, R. M. (2004) · doi:10.1128/9781555817657.ch2 · Cited by 31 · see citing works

Old and New TB Drugs: Mechanisms of Action and Resistance

Anastasia, S., & Petros, C. (2012) · InTech eBooks · doi:10.5772/30992 · Cited by 30 · see citing works

Antituberculosis therapy for 2012 and beyond

Lauzardo, M., & Peloquin, C. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.657176 · Cited by 24 · see citing works

Inhalation Drug Delivery

(2013) · Wiley eBooks · doi:10.1002/9781118397145 · Cited by 23 · see citing works

[Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis].

Kurunov, I. N., Ursov, I. G., Va, K., Petrenko, T. I., Nn, I., Владимирович, С. А., & Pa, F. (1995) · PubMed · Cited by 21 · see citing works

Formulation and evalution of montelukast sodium - chitosan based spray dried microspheres for pulmonary drug delivery

Panchal, R., Patel, H., Patel, V. A., Joshi, P. U., & Parikh, A. R. (2012) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.94160 · Cited by 20 · see citing works

INFLUENCE OF FORMULATION COMPONENTS ON AEROSOLIZATION PROPERTIES OF ISONIAZID LOADED CHITOSAN MICROSPHERES

Kundawala, A. J., Patel, V. A., Patel, H. V., & Choudhary, D. (2018) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2011.030405 · Cited by 16 · see citing works

Quinolones for mycobacterial infections

Rubinstein, E., & Keynan, Y. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.03.005 · Cited by 12 · see citing works

Pathogenesis of tuberculosis

Venkataraman, M. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90142-t · Cited by 10 · see citing works

PREPARATION OF ISONIAZID AS DRY POWDER FORMULATIONS FOR INHALATION BY PHYSICAL MIXING AND SPRAY DRYING

Sawatdee, S., Worakul, N., & Srichana, T. (2006) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 9 · see citing works

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 499 · see citing works

The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases

Nisini, R., Poerio, N., Mariotti, S., Santis, F. D., & Fraziano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00155 · Cited by 299 · see citing works

A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases

He, S., Gui, J., Xiong, K., Chen, M., Gao, H., & Fu, Y. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01307-x · Cited by 188 · see citing works

Soy Lecithin-Derived Liposomal Delivery Systems: Surface Modification and Current Applications

Le, N. T. T., Cao, V. D., Nguyen, T. N. Q., Le, T. T. H., Tran, T. T., & Thi, T. T. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194706 · Cited by 180 · see citing works

Versatility of hydrogel-forming microneedles in in vitro transdermal delivery of tuberculosis drugs

Anjani, Q. K., Permana, A. D., Cárcamo-Martínez, Á., Domínguez‐Robles, J., Tekko, I. A., Larrañeta, E., Vora, L. K., Ramadon, D., & Donnelly, R. F. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.12.003 · Cited by 148 · see citing works

A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers

Mohd, R. R., Muniandy, M. T., Zakaria, Z., Shah, K. U., Chee, C. F., Dabbagh, A., Rahman, N. A., & Wong, T. W. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116800 · Cited by 139 · see citing works

The formulation of nanomedicines for treating tuberculosis

Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123 · see citing works

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles

Costa-Gouveia, J., Pancani, E., Jouny, S., Machelart, A., Delorme, V., Salzano, G., Iantomasi, R., Piveteau, C., Queval, C. J., Song, O., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05453-3 · Cited by 102 · see citing works

Pulmonary inhalation for disease treatment: Basic research and clinical translations

Wang, B., Wang, L., Yang, Q., Zhang, Y., Qinglai, T., Yang, X., Xiao, Z., Lei, L., & Li, S. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.100966 · Cited by 98 · see citing works

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Nair, A., Greeny, A., Nandan, A., Sah, R. K., Jose, A., Dyawanapelly, S., Junnuthula, V., Athira, K. V., & Sadanandan, P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02156-y · Cited by 99 · see citing works

Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment

Shah, K. U., Chan, L. W., & Wong, T. W. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1384298 · Cited by 90 · see citing works

Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis

Abdelghany, S. M., Parumasivam, T., Pang, A., Roediger, B., Tang, P., Jahn, K. A., Britton, W. J., & Chan, H. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.05.025 · Cited by 89 · see citing works

Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies

Kumar, M., Virmani, T., Kumar, G., Deshmukh, R., Sharma, A., Duarte, S. O. D., Brandão, P., & Fonte, P. (2023) · Pharmaceuticals · doi:10.3390/ph16101360 · Cited by 87 · see citing works

Iron-Based Metal-Organic Frameworks as a Theranostic Carrier for Local Tuberculosis Therapy

Wyszogrodzka, G., Dorożyński, P., Gil, B., Roth, W. J., Strzempek, M., Marszałek, B., Węglarz, W. P., Menaszek, E., Strzempek, W., & Kulinowski, P. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2425-2 · Cited by 82 · see citing works

Engineering of Nebulized Metal–Phenolic Capsules for Controlled Pulmonary Deposition

Ju, Y., Cortez‐Jugo, C., Chen, J., Wang, T., Mitchell, A. J., Tsantikos, E., Bertleff‐Zieschang, N., Lin, Y., Song, J., Cheng, Y., et al. (2020) · Advanced Science · doi:10.1002/advs.201902650 · Cited by 77 · see citing works

An Inhalable Theranostic System for Local Tuberculosis Treatment Containing an Isoniazid Loaded Metal Organic Framework Fe-MIL-101-NH2—From Raw MOF to Drug Delivery System

Wyszogrodzka, G., Dorożyński, P., Giovagnoli, S., Strzempek, W., Pesta, E., Węglarz, W. P., Gil, B., Menaszek, E., & Kulinowski, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11120687 · Cited by 75 · see citing works

A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?

Maniar, K., Moideen, A., Mittal, A., Patil, A., Chakrabarti, A., & Banerjee, D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.003 · Cited by 75 · see citing works

Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity

Carneiro, S. P., Carvalho, K. V., Aguiar‐Soares, R. D. D. O., Carneiro, C. M., de Andrade, M. H. G., Duarte, R. S., & dos Santos, O. D. H. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.12.003 · Cited by 73 · see citing works

Pulmonary delivery of rifampicin-loaded soluplus micelles against Mycobacterium tuberculosis

Grotz, E., Tateosian, N. L., Salgueiro, J., Bernabeu, E., González, L., Manca, M. L., Amiano, N. O., Valenti, D., Manconi, M., García, V., et al. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101170 · Cited by 71 · see citing works

How can nanoparticles contribute to antituberculosis therapy?

Costa-Gouveia, J., Aínsa, J. A., Brodin, P. M., & Lucía, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.011 · Cited by 68 · see citing works

Triple co-culture of human alveolar epithelium, endothelium and macrophages for studying the interaction of nanocarriers with the air-blood barrier

Costa, A., Carvalho‐Wodarz, C. D. S., Seabra, V., Sarmento, B. F. C. C., & Lehr, C. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.04.037 · Cited by 66 · see citing works

Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α- d -mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy

Maretti, E., Costantino, L., Rustichelli, C., Leo, E., Croce, M. A., Buttini, F., Truzzi, E., & Iannuccelli, V. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.045 · Cited by 64 · see citing works

In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?

Truzzi, E., Nascimento, T. L., Iannuccelli, V., Costantino, L., Lima, E. M., Leo, E., Siligardi, C., Gualtieri, M. L., & Maretti, E. (2020) · Nanomaterials · doi:10.3390/nano10030568 · Cited by 63 · see citing works

Solidified SNEDDS for the oral delivery of rifampicin: Evaluation, proof of concept, in vivo kinetics, and in silico GastroPlusTM simulation

Hussain, A., Shakeel, F., Singh, S. K., Alsarra, I. A., Faruk, A., Alanazi, F. K., & Christoper, G. V. P. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.061 · Cited by 63 · see citing works

Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly(ester amide)s nanocarriers

Praphakar, R. A., Munusamy, M. A., Sadasivuni, K. K., & Rajan, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.080 · Cited by 62 · see citing works

Benzalkonium chloride alters phenotypic and genotypic antibiotic resistance profiles in a source water used for drinking water treatment

Harrison, K. R., Kappell, A. D., & McNamara, P. J. (2019) · Environmental Pollution · doi:10.1016/j.envpol.2019.113472 · Cited by 58 · see citing works

Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis

Chae, J., Choi, Y., Tanaka, M., & Choi, J. H. (2021) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2021.08.009 · Cited by 56 · see citing works

Extended Release of Highly Water Soluble Isoniazid Attained through Cocrystallization with Curcumin

Xuan, B., Wong, S. N., Zhang, Y., Weng, J., Tong, H. H. Y., Wang, C., Sun, C. C., & Chow, S. F. (2020) · Crystal Growth & Design · doi:10.1021/acs.cgd.9b01619 · Cited by 56 · see citing works

Lessons from black pepper: piperine and derivatives thereof

Chavarria, D., Silva, T., Silva, D., Remião, F., & Borges, F. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1118057 · Cited by 54 · see citing works

High dose dry powder inhalers to overcome the challenges of tuberculosis treatment

Momin, M. A. M., Tucker, I. G., & Das, S. C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.08.061 · Cited by 53 · see citing works

Role of Novel Drug Delivery Vehicles in Nanobiomedicine

Tyagi, R. K. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77468 · Cited by 50 · see citing works

Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatmentA Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability

Maretti, E., Rustichelli, C., Romagnoli, M., Balducci, A. G., Buttini, F., Sacchetti, F., Leo, E., & Iannuccelli, V. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.07.062 · Cited by 49 · see citing works

Innovative Therapeutic Approaches Based on Nanotechnology for the Treatment and Management of Tuberculosis

Kia, P., Ruman, U., Pratiwi, A. R., & Hussein, M. Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s364634 · Cited by 51 · see citing works

Inhalable Antitubercular Therapy Mediated by Locust Bean Gum Microparticles

Alves, A. P. N. N., Cavaco, J., Guerreiro, F., Lourenço, J. P., da Costa, A. M. R., & Grenha, A. (2016) · Molecules · doi:10.3390/molecules21060702 · Cited by 48 · see citing works

Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: Design, development and in vitro evaluation

Shah, S. R., Cristopher, D., Sharma, S., Soniwala, M. M., & Chavda, J. R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102013 · Cited by 48 · see citing works

Analysis of cohesion forces between monodisperse microparticles with rough surfaces

Baldelli, A., & Vehring, R. (2016) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2016.06.009 · Cited by 47 · see citing works

Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis

Momin, M. A. M., Sinha, S., Tucker, I. G., Doyle, C., & Das, S. C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.004 · Cited by 47 · see citing works

Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections

Momin, M. A. M., Tucker, I. G., Doyle, C., Denman, J. A., Sinha, S., & Das, S. C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.02.026 · Cited by 47 · see citing works

Nanotechnology in Drug Discovery and Development

Gutiérrez, L., Stepien, G., Gutiérrez, L., Pérez-Hernández, M., Pardo, J., Pardo, J., Grazú, V., & de la Fuente, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12292-9 · Cited by 46 · see citing works

DPI formulations for high dose applications – Challenges and opportunities

Scherließ, R., & Etschmann, C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.038 · Cited by 46 · see citing works

Antimicrobial polymeric biomaterials based on synthetic, nanotechnology, and biotechnological approaches

Rojo, L., García‐Fernández, L., Aguilar, M. R., & Vázquez‐Lasa, B. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102752 · Cited by 45 · see citing works

Development of Inhalable Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Microparticulate System for Antituberculosis Drug Delivery

Miranda, M. S., Rodrigues, M. T., Domingues, R. M. A., Costa, R. R., Paz, E., Rodríguez‐Abreu, C., Freitas, P. P., Almeida, B. G., Carvalho, M. A., Gonçalves, C. M., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800124 · Cited by 45 · see citing works

Chronic respiratory diseases: An introduction and need for novel drug delivery approaches

Shukla, S. D., Vanka, K. S., Chavelier, A., Shastri, M. D., Tambuwala, M. M., Bakshi, H. A., Pabreja, K., Mahmood, M. Q., & O’Toole, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00001-7 · Cited by 47 · see citing works

Inhalable liposomes ofGlycyrrhiza glabraextract for use in tuberculosis: formulation,in vitrocharacterization,in vivolung deposition, andin vivopharmacodynamic studies

Viswanathan, V., Pharande, R. R., Bannalikar, A. S., Gupta, P., Gupta, U. D., & Mukne, A. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1513025 · Cited by 43 · see citing works

Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19

Alipour, S., Mahmoudi, L., & Ahmadi, F. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01251-1 · Cited by 42 · see citing works

The Anti-Tuberculosis Agents Under Development and the Challenges Ahead

Kumar, D., Negi, B., & Rawat, D. S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.128 · Cited by 42 · see citing works

Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery

Miranda, M. S., Rodrigues, M. T., Domingues, R. M. A., Torrado, E., Reis, R. L., Pedrosa, J., & Gomes, M. E. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.09.004 · Cited by 42 · see citing works

Spray-drying of konjac glucomannan to produce microparticles for an application as antitubercular drug carriers

Guerreiro, F., Pontes, J. F., da Costa, A. M. R., & Grenha, A. (2018) · Powder Technology · doi:10.1016/j.powtec.2018.09.068 · Cited by 42 · see citing works

Beyond “Big Eaters”: The Versatile Role of Alveolar Macrophages in Health and Disease

Hetzel, M., Ackermann, M., & Lachmann, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073308 · Cited by 37 · see citing works

Pulmonary delivery of pyrazinamide-loaded large porous particles

Pham, D.-D., Grégoire, N., Couet, W. R., Gueutin, C., Fattal, E., & Tsapis, N. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.021 · Cited by 39 · see citing works

Polymeric nanotherapeutics acting at special regions of body

Feczkó, T. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102597 · Cited by 38 · see citing works

Enhanced antitubercular activity, alveolar deposition and macrophages uptake of mannosylated stable nanoliposomes

Hamed, A. I., Osman, R., Al‐Jamal, K. T., Holayel, S. M., & Geneidi, A. S. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.03.032 · Cited by 37 · see citing works

Metal–Organic Framework Microsphere Formulation for Pulmonary Administration

Fernández-Paz, C., Rojas, S., Salcedo‐Abraira, P., Simón‐Yarza, T., Remuñán‐López, C., & Horcajada, P. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c07356 · Cited by 37 · see citing works

Fullerene nanoparticles: a promising candidate for the alleviation of silicosis-associated pulmonary inflammation

Liu, S., Chen, D., Li, X., Guan, M., Zhou, Y., Li, L., Jia, W., Zhou, C., Shu, C., Wang, C., et al. (2020) · Nanoscale · doi:10.1039/d0nr04401f · Cited by 37 · see citing works

Nanopolymersomes as potential carriers for rifampicin pulmonary delivery

Moretton, M. A., Cagel, M., Bernabeu, E., González, L., & Chiappetta, D. A. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.10.049 · Cited by 36 · see citing works

Rifampicin Nanoformulation Enhances Treatment of Tuberculosis in Zebrafish

Trousil, J., Syrová, Z., Dal, N. K., Rak, D., Konefał, R., Pavlová, E., Matějková, J., Cmarko, D., Kubíčková, P., Pavliš, O., et al. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00214 · Cited by 36 · see citing works

Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin

Bera, H., Zhao, C., Tian, X., Cun, D., & Yang, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030429 · Cited by 35 · see citing works

Targeted delivery of anti-tuberculosis drugs to macrophages: targeting mannose receptors

Filatova, L. Y., Klyachko, N. L., & Kudryashova, E. V. (2018) · Russian Chemical Reviews · doi:10.1070/rcr4740 · Cited by 35 · see citing works

Nano-based drug delivery optimization for tuberculosis treatment: A review

Dahanayake, M. H., & Jayasundera, A. C. A. (2020) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2020.106127 · Cited by 35 · see citing works

A comparative physicochemical, morphological and magnetic study of silane-functionalized superparamagnetic iron oxide nanoparticles prepared by alkaline coprecipitation

Mireles, L. K., Sacher, E., Yahia, L., Laurent, S., & Stanicki, D. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.12.002 · Cited by 35 · see citing works

Current advances in drug delivery of nanoparticles for respiratory disease treatment

de Menezes, B. R. C., Rodrigues, K. F., Schatkoski, V. M., Pereira, R. M., Ribas, R. G., Montanheiro, T. L. D. A., & Thim, G. P. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01783c · Cited by 34 · see citing works

Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study

Zhou, S.-F., Niu, N., Yin, J., Yang, Y., Wang, Z., Zhou, Z.-W., He, Z., Chen, X., Zhang, X., Duan, W., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s79369 · Cited by 34 · see citing works

Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates

Carvalho, R. D. S. F., Pereira, M. A., Linhares, L. D. A., Nogueira, M. C. D. B. L., Cavalcanti, I. M. F., Santos-Magalhães, N. S., & Montenegro, L. M. L. (2016) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760150454 · Cited by 33 · see citing works

A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation

Khadka, P., Dummer, J. F., Hill, P. C., Katare, R., & Das, S. C. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01238-y · Cited by 32 · see citing works

Drug Delivery for tuberculosis: is Inhaled Therapy the Key to success?

Traini, D., & Young, P. M. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0050 · Cited by 31 · see citing works

Active pulmonary targeting against tuberculosis (TB) via triple-encapsulation of Q203, bedaquiline and superparamagnetic iron oxides (SPIOs) in nanoparticle aggregates

Poh, W., Rahman, N. B. A., Ostrovski, Y., Sznitman, J., Pethe, K., & Loo, S. C. J. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1676841 · Cited by 29 · see citing works

Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection

Grenha, A., Alves, A. D., Guerreiro, F., Pinho, J. O., Simões, S., Almeida, A. J., & Gaspar, M. M. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.11.009 · Cited by 29 · see citing works

Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis

Verma, N., Arora, V., Awasthi, R., Chan, Y., Jha, N. K., Thapa, K., Jawaid, T., Kamal, M., Gupta, G., Liu, G., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103690 · Cited by 29 · see citing works

Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review

Elella, M. H. A., Khatib, A. O. A., & Al-Obaidi, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050680 · Cited by 29 · see citing works

Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment

Kalombo, L., Lemmer, Y., Semete‐Makokotlela, B., Ramalapa, B., Nkuna, P., Booysen, L., Naidoo, S., Hayeshi, R. K., Verschoor, J. A., & Swai, H. (2019) · Nanomaterials · doi:10.3390/nano9081167 · Cited by 28 · see citing works

Strategies for lipid-based nanocomposites with potential activity against Mycobacterium tuberculosis: Microbial resistance challenge and drug delivery trends

Hatae, A. C., Roque‐Borda, C. A., & Pavan, F. R. (2023) · OpenNano · doi:10.1016/j.onano.2023.100171 · Cited by 28 · see citing works

Future of nanomedicines for treating respiratory diseases

Scherließ, R. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1553955 · Cited by 27 · see citing works

Liposomes-and niosomes-based drug delivery systems for tuberculosis treatment

Bekraki, A. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00007-2 · Cited by 28 · see citing works

Dry powder inhalation formulation of chitosan nanoparticles for co-administration of isoniazid and pyrazinamide

Changsan, N., & Sinsuebpol, C. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1852570 · Cited by 27 · see citing works

Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation

Garg, T., Goyal, A. K., Rath, G., & Murthy, R. S. R. (2015) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2015.1081613 · Cited by 26 · see citing works

Electrostatically entrapped colistin liposomes for the treatment of Pseudomonas aeruginosa infection

Yang, L., Tang, C., Zhang, E., & Yang, L. (2016) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2016.1228666 · Cited by 25 · see citing works

Pharmacokinetics and in vivo distribution of optimized PLGA nanoparticles for pulmonary delivery of levofloxacin

Shah, S. R., Prajapati, H. R., Sheth, D. B., Gondaliya, E. M., Vyas, A. J., Soniwala, M. M., & Chavda, J. R. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13275 · Cited by 25 · see citing works

Breathing new life nanomedicines for pulmonary drug delivery: targeting approaches, experimental models, and regulatory aspects

Gholap, A. D., Pardeshi, S. R., Giram, P. S., Nangare, S., Sodha, S., Kapare, H. S., More, M. P., Sonar, Y. A., Shukla, R., Naik, J., et al. (2025) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-025-00646-6 · Cited by 25 · see citing works

Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis

Man, D. K.-W., Chow, M. Y. T., Casettari, L., Juarrero, M. G., & Lam, J. K. W. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.013 · Cited by 25 · see citing works

Efficient loading of ethionamide in cyclodextrin-based carriers offers enhanced solubility and inhibition of drug crystallization

Wankar, J., Salzano, G., Pancani, E., Benkovics, G., Malanga, M., Manoli, F., Gref, R., Fenyvesi, É., & Manet, I. G. J. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.041 · Cited by 24 · see citing works

Drug delivery systems for fluoroquinolones: New prospects in tuberculosis treatment

Le‐Deygen, I. M., Скуредина, А. А., & Kudryashova, E. V. (2017) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162017050077 · Cited by 24 · see citing works

Evaluating the biomolecular interaction between delamanid/formulations and human serum albumin by fluorescence, CD spectroscopy and SPR: Effects on protein conformation, kinetic and thermodynamic parameters

Tongkanarak, K., Loupiac, C., Neiers, F., Chambin, O., & Srichana, T. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.113964 · Cited by 23 · see citing works

In silico identification and synthesis of a multi-drug loaded MOF for treating tuberculosis

Acharya, A. P., Sezginel, K. B., Gideon, H. P., Greene, A. C., Lawson, H., Inamdar, S., Tang, Y., Fraser, A. J., Patel, K. V., Liu, C., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.024 · Cited by 22 · see citing works

Chitosan-based pulmonary particulate systems for anticancer and antiviral drug carriers: A promising delivery for COVID-19 vaccines

Tousian, B., & Khosravi, A. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101146 · Cited by 21 · see citing works

Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis

Sheikh, B. A., Bhat, B. A., Alshehri, B., Mir, R. A., Mir, W. R., Parry, Z. A., & Mir, M. A. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3201 · Cited by 20 · see citing works

Polymeric micelle-based drug delivery systems for tuberculosis treatment

Gorain, B., Choudhury, H., Sisinthy, S. P., & Kesharwani, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00011-4 · Cited by 20 · see citing works

Influence of Drug Properties and Routes of Drug Administration on the Design of Controlled Release System

Indurkhya, A., Patel, M., Sharma, P. A., Abed, S. N., Shnoudeh, A. J., Maheshwari, R., Deb, P. K., & Tekade, R. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814423-7.00006-x · Cited by 19 · see citing works

Lipid nanoparticles with improved biopharmaceutical attributes for tuberculosis treatment

Gordillo-Galeano, A., Ospina-Giraldo, L. F., & Mora‐Huertas, C. E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120321 · Cited by 19 · see citing works

The Activity of a Hexameric M17 Metallo-Aminopeptidase Is Associated With Survival of Mycobacterium tuberculosis

Corrêa, A. F., Bastos, I. M. D., Neves, D., Kipnis, A., Junqueira‐Kipnis, A. P., & Santana, J. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00504 · Cited by 18 · see citing works

The long and winding road to inhaled TB therapy: not only the bug’s fault

Giovagnoli, S., Schoubben, A., & Ricci, M. (2016) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2016.1272119 · Cited by 17 · see citing works

The Role of Metallic Nanoparticles in Inhibition of Mycobacterium Tuberculosis and Enhances Phagosome Maturation into the Infected Macrophage

Jafari, A., Nagheli, A., Foumani, A. A., Tehrani, B. S., & Goswami, R. (2020) · Oman Medical Journal · doi:10.5001/omj.2020.78 · Cited by 17 · see citing works

Solubility Enhancement and Inhalation Delivery of Cyclodextrin-Based Inclusion Complex of Delamanid for Pulmonary Tuberculosis Treatment

Patil, S. M., Barji, D. S., Chavan, T., Patel, K., Collazo, A. J., Prithipaul, V., Muth, A., & Kunda, N. K. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02510-1 · Cited by 17 · see citing works

Manufacturing processes for polymeric micro and nanoparticles and their biomedical applications

Braz, A. L., & Ahmed, I. (2017) · AIMS bioengineering · doi:10.3934/bioeng.2017.1.46 · Cited by 17 · see citing works

Preference of inhalants over pills/injections among pulmonary tuberculosis patients in Western India: A cross-sectional study

Ahuja, N. A., Sznajder, K. K., Patil, R., & Shaikh, B. (2021) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2021.100234 · Cited by 16 · see citing works

Carrier Effect in Development of Rifampin Loaded Proliposome for Pulmonary Delivery: A Quality by Design Study

Parhizkar, E., Sadeghinia, D., Hamishehkar, H., Yaqoubi, S., Nokhodchi, A., & Alipour, S. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.032 · Cited by 16 · see citing works

Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation

Momin, M. A. M., Rangnekar, B., & Das, S. C. (2018) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2018.1437748 · Cited by 16 · see citing works

Pulmonary Delivery of Linezolid Nanoparticles for Treatment of Tuberculosis: Design, Development, and Optimization

Shah, S. R., Maheshwari, H., Soniwala, M. M., & Chavda, J. R. (2020) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-020-09491-9 · Cited by 16 · see citing works

Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics

Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 15 · see citing works

Data-Driven Prediction of the Formation of Co-Amorphous Systems

Fink, E., Brunsteiner, M., Mitsche, S., Schröttner, H., Paudel, A., & Zellnitz, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020347 · Cited by 15 · see citing works

Tuberculosis and HIV Infection

Johnson, M. D., & Decker, C. F. (2006) · Disease-a-Month · doi:10.1016/j.disamonth.2006.09.006 · Cited by 36 · see citing works

Advancement in pulmonary drug delivery systems for treatment of tuberculosis

Goyal, A. K., Garg, T., Bhandari, S., & Rath, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00022-1 · Cited by 25 · see citing works

Review On Pulmonary Drug Delivery Systems For Tuberculosis: Advances In Dry Powder Inhalers And Emerging Nanoparticles Strategies

Bhavnani, G., Suryawanshi, A., Mandpe, P., Wadile, C., Bodas, D., & Banait, V. (2025) · International Journal of Research Publication and Reviews · doi:10.55248/gengpi.6.1025.3666

THE POTENTIAL ADVANTAGES OF SOLID LIPID NANOPARTICLES IN CHEMOTHERAPY OF TUBERCULOSIS

Sansare, V. A., & Kanavaje, A. M. (2019) · Indian Research Journal of Pharmacy and Science · doi:10.21276/irjps.2019.6.3.8

Inhaled Dry Powder Formulations for Treating Tuberculosis

Das, S. C., Tucker, I. G., & Stewart, P. (2015) · Current Drug Delivery · doi:10.2174/1567201811666140716123050 · Cited by 51 · see citing works